Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06282107
Other study ID # BiSAAE-RHT
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date January 1, 2025
Est. completion date December 31, 2026

Study information

Verified date February 2024
Source First Affiliated Hospital of Chengdu Medical College
Contact Yaqiong Zhou
Phone +8615184399329
Email 1273868593@qq.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Hypertension is a common problem, affecting >1.1 billion people worldwide. Unfortunately, fewer than one in five treated patients with hypertension have their blood pressure (BP) under control. The increasing number of people with uncontrolled BP despite the use of three or more antihypertensive agents at optimal or maximally tolerated doses, with one of those agents preferably being a diuretic has been described as the resistant hypertension (RH). Achieving BP control is essential because patients with hypertension who have uncontrolled BP have significantly higher rates of all-cause, cardiovascular, heart disease and cerebrovascular disease mortality compared to normotensive individuals, whereas mortality risk in patients with well-controlled BP does not differ from that in normotensive individuals. There are a number of potential factors that contribute to the suboptimal control of hypertension, including medication non-adherence and prescribing inertia. This highlights the limitations of purely pharmacological approaches for the effective management of hypertension. In fact, the activation of the renin-angiotensin-aldosterone system (RAAS) and sympatho-adrenomedullary system play a pathogenic role in triggering and sustaining RH. Superselective adrenal arterial embolization (SAAE) is a catheter-based percutaneous transluminal procedure which selectively injects ethanol into adrenal artery to ablate part of the adrenal gland for suppression of excessive aldosterone and catecholamines. Over the last decade, unilateral SAAE has emerged as a potential treatment option for patients with primary aldosteronism. Whether this approach can be extrapolated to patients with RH is unclear. We thus set out to perform a randomized trial to compare the safety and efficacy of bilateral SAAE with antihypertensive medications in treating RH.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 72
Est. completion date December 31, 2026
Est. primary completion date June 30, 2025
Accepts healthy volunteers No
Gender All
Age group 30 Years to 65 Years
Eligibility Inclusion Criteria: - Male or female, aged between 30-65 years old. - Patients with resist hypertension (office systolic blood pressure =140 mmHg, and/or office diastolic blood pressure =90 mmHg, and/or 24-h average systolic blood pressure =130 mmHg) with rational lifestyle change and triple antihypertensive drugs (irbesartanhydrochlorothiazide 162.5 mg/d, amlodipine 5 mg/d) for at least 4 weeks. - Informed consent signed and agreed to participate in this trial. Exclusion Criteria: - Secondary hypertension - Adrenergic insufficiency. - adrenocortical insufficiency - Renal failure eGFR<60 mL/min/1.73 m2 - Heart failure with NYHA grade ?-? grade or unstable angina, severe cardiovascular and cerebrovascular stenosis, myocardial infarction, intracranial aneurysm, stroke and other acute cardiovascular events. - Acute infections, tumors and severe arrhythmias, psychiatric disorders, drugs or alcohol addicts. - Liver dysfunction or the following history of liver disease: AST or ALT 3 times higher than the upper limit, liver cirrhosis, history of hepatic encephalopathy, esophageal variceal history or portal shunt history. - Fertile woman without contraceptives. - Coagulation dysfunction. - Pregnant women or lactating women. - Participated in other clinical trials or admitted with other research drugs within 3 months prior to the trial. - Any surgical or medical condition which can significantly alter the absorption, distribution, metabolism, or excretion of any study drug. - Allergy or any contraindications for the study drugs, contrast agents and alcohol. History of depression, schizophrenia or vascular dementia. -Refused to sign informed consent

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
BiSAAE
SAAE is a catheter-based percutaneous transluminal procedure which selectively injects ethanol into bilateral adrenal artery to ablate part of the adrenal gland for suppression of excessive aldosterone and catecholamines
traditional triple antihypertensive treatment
traditional triple antihypertensive treatment

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
First Affiliated Hospital of Chengdu Medical College

References & Publications (4)

Wang X, Luo T, Yang Y, Zhou Y, Hou J, Wang P. Unilateral chemical ablation of the adrenal gland lowers blood pressure and alleviates target organ damage in spontaneously hypertensive rats. Hypertens Res. 2023 Dec;46(12):2693-2704. doi: 10.1038/s41440-023-01444-2. Epub 2023 Oct 3. — View Citation

Zhou Y, Liu Q, Wang X, Wan J, Liu S, Luo T, He P, Hou J, Pu J, Wang D, Liang D, Yang Y, Wang P. Adrenal Ablation Versus Mineralocorticoid Receptor Antagonism for the Treatment of Primary Aldosteronism: A Single-Center Prospective Cohort Study. Am J Hypertens. 2022 Dec 8;35(12):1014-1023. doi: 10.1093/ajh/hpac105. — View Citation

Zhou Y, Wang D, Liu Q, Hou J, Wang P. Case report: Percutaneous adrenal arterial embolization cures resistant hypertension. Front Cardiovasc Med. 2022 Oct 11;9:1013426. doi: 10.3389/fcvm.2022.1013426. eCollection 2022. — View Citation

Zhou Y, Wang X, Hou J, Wan J, Yang Y, Liu S, Luo T, Liu Q, Xue Q, Wang P. A controlled trial of percutaneous adrenal arterial embolization for hypertension in patients with idiopathic hyperaldosteronism. Hypertens Res. 2024 Feb;47(2):311-321. doi: 10.1038/s41440-023-01420-w. Epub 2023 Aug 29. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Change of 24-h average systolic blood pressure Difference in the change of 24-h average systolic blood pressure between the intervention and control group 6-month
Primary Change of 24-h average systolic blood pressure Difference in the change of 24-h average systolic blood pressure between the intervention and control group 12-month
Primary Change of 24-h average systolic blood pressure Difference in the change of 24-h average systolic blood pressure between the intervention and control group 3-month
Secondary Change of 24-h average diastolic blood pressure, daytime mean systolic blood pressure, daytime mean diastolic blood pressure, and nighttime average systolic and diastolic blood pressure Difference in the change of 24-h average diastolic blood pressure, daytime mean systolic blood pressure, daytime mean diastolic blood pressure, and nighttime average systolic and diastolic blood pressure between the intervention and control group 6-month
Secondary Change of 24-h average diastolic blood pressure, daytime mean systolic blood pressure, daytime mean diastolic blood pressure, and nighttime average systolic and diastolic blood pressure Difference in the change of 24-h average diastolic blood pressure, daytime mean systolic blood pressure, daytime mean diastolic blood pressure, and nighttime average systolic and diastolic blood pressure between the intervention and control group 3-month
Secondary Change of 24-h average diastolic blood pressure, daytime mean systolic blood pressure, daytime mean diastolic blood pressure, and nighttime average systolic and diastolic blood pressure Difference in the change of 24-h average diastolic blood pressure, daytime mean systolic blood pressure, daytime mean diastolic blood pressure, and nighttime average systolic and diastolic blood pressure between the intervention and control group 12-month
Secondary Change of home systolic and diastolic pressure Difference in the change of home systolic and diastolic pressure between the intervention and control group 6-month
Secondary Change of home systolic and diastolic pressure Difference in the change of home systolic and diastolic pressure between the intervention and control group 12-month
Secondary Change of home systolic and diastolic pressure Difference in the change of home systolic and diastolic pressure between the intervention and control group 3-month
Secondary Difference in the change of office systolic and diastolic pressure between the intervention and control group Difference in the change of office systolic and diastolic pressure between the intervention and control group 6-month
Secondary Difference in the change of office systolic and diastolic pressure between the intervention and control group Difference in the change of office systolic and diastolic pressure between the intervention and control group 12-month
Secondary Difference in the change of office systolic and diastolic pressure between the intervention and control group Difference in the change of office systolic and diastolic pressure between the intervention and control group 3-month
Secondary Difference in the change of blood electrolytes (K+, Na + in mmol/L) between the intervention and control group Difference in the change of blood electrolytes (K+, Na + in mmol/L) between the intervention and control group 6-month
Secondary Difference in the change of blood electrolytes (K+, Na + in mmol/L) between the intervention and control group Difference in the change of blood electrolytes (K+, Na + in mmol/L) between the intervention and control group 12-month
Secondary Difference in the change of blood electrolytes (K+, Na + in mmol/L) between the intervention and control group Difference in the change of blood electrolytes (K+, Na + in mmol/L) between the intervention and control group 3-month
Secondary Change of plasma aldosterone Difference in the change of plasma aldosterone (pg/mL) between the intervention and control group 6-month
Secondary Change of plasma aldosterone Difference in the change of plasma aldosterone (pg/mL) between the intervention and control group 12-month
Secondary Change of plasma aldosterone Difference in the change of plasma aldosterone (pg/mL) between the intervention and control group 3-month
Secondary Change of plasma cortisol Change of plasma cortisol 6-month
Secondary Change of plasma cortisol Change of plasma cortisol 12-month
Secondary Change of plasma cortisol Change of plasma cortisol 3-month
Secondary Change of plasma renin measured Difference in the change of plasma renin (pg/ml) between the intervention and control group 6-month
Secondary Change of plasma renin measured Difference in the change of plasma renin (pg/ml) between the intervention and control group 12-month
Secondary Change of plasma renin measured Difference in the change of plasma renin (pg/ml) between the intervention and control group 3-month
Secondary Change of liver enzymes Difference in the change of liver enzymes (ALT, AST in IU/L) between the intervention and control group 6-month
Secondary Change of liver enzymes Difference in the change of liver enzymes (ALT, AST in IU/L) between the intervention and control group 12-month
Secondary Change of liver enzymes Difference in the change of liver enzymes (ALT, AST in IU/L) between the intervention and control group 3-month
Secondary Change of kidney function Difference in the change of serum creatinine in umol/L between the intervention and control group 6-month
Secondary Change of kidney function Difference in the change of serum creatinine in umol/L between the intervention and control group 12-month
Secondary Change of kidney function Difference in the change of serum creatinine in umol/L between the intervention and control group 3-month
Secondary Change of fasting blood glucose Difference in the change of fasting blood glucose in mmol/L between the intervention and control group 6-month
Secondary Change of fasting blood glucose Difference in the change of fasting blood glucose in mmol/L between the intervention and control group 3-month
Secondary Change of fasting blood glucose Difference in the change of fasting blood glucose in mmol/L between the intervention and control group 12-month
Secondary Change of lipids profiles Difference in the change of lipids profiles (TC, HDL-C, LDL-C, TG) in mmol/L between the intervention and control group 6-month
Secondary Change of lipids profiles Difference in the change of lipids profiles (TC, HDL-C, LDL-C, TG) in mmol/L between the intervention and control group 12-month
Secondary Change of lipids profiles Difference in the change of lipids profiles (TC, HDL-C, LDL-C, TG) in mmol/L between the intervention and control group 3-month
Secondary Change of echocardiography parameters (IVSd?IVSs?LVPWd, LVPWs, LVEDD) Difference in the change of echocardiography parameters (IVSd?IVSs?LVPWd, LVPWs, LVEDD, in millimetre[mm]) between the intervention and control group 6-month
Secondary Change of echocardiography parameters (IVSd?IVSs?LVPWd, LVPWs, LVEDD) Difference in the change of echocardiography parameters (IVSd?IVSs?LVPWd, LVPWs, LVEDD, in millimetre[mm]) between the intervention and control group 12-month
Secondary Change of echocardiography parameters (IVSd?IVSs?LVPWd, LVPWs, LVEDD) Difference in the change of echocardiography parameters (IVSd?IVSs?LVPWd, LVPWs, LVEDD, in millimetre[mm]) between the intervention and control group 3-month
Secondary Change of 24-h urine microalbumin Difference in the change of 24-h urine microalbumin (mg/L) between the intervention and control group 6-month
Secondary Change of 24-h urine microalbumin Difference in the change of 24-h urine microalbumin (mg/L) between the intervention and control group 12-month
Secondary Change of 24-h urine microalbumin Difference in the change of 24-h urine microalbumin (mg/L) between the intervention and control group 3-month
Secondary Change of 24-h urine creatinine Difference in the change of 24-h urine creatinine (umol/L) between the intervention and control group 6-month
Secondary Change of 24-h urine creatinine Difference in the change of 24-h urine creatinine (umol/L) between the intervention and control group 12-month
Secondary Change of 24-h urine creatinine Difference in the change of 24-h urine creatinine (umol/L) between the intervention and control group 3-month
Secondary Change of echocardiography parameters (LVEF) Change of echocardiography parameters (LVEF) 6-month
Secondary Change of echocardiography parameters (LVEF) Change of echocardiography parameters (LVEF) 12-month
Secondary Change of echocardiography parameters (LVEF) Change of echocardiography parameters (LVEF) 3-month
Secondary Change of carotid intima-media thickness Difference in the change of carotid intima-media thickness(CIMT) assessed by carotid ultrasound between the intervention and control group 6-month
Secondary Change of carotid intima-media thickness Difference in the change of carotid intima-media thickness(CIMT) assessed by carotid ultrasound between the intervention and control group 12-month
Secondary Change of carotid intima-media thickness Difference in the change of carotid intima-media thickness(CIMT) assessed by carotid ultrasound between the intervention and control group 3-month
See also
  Status Clinical Trial Phase
Recruiting NCT05545059 - Effects and Safety of Sacubitril/Valsartan on Refractory Hypertension Phase 3
Not yet recruiting NCT04388124 - VASCULAR AND RENAL IMPACT OF ENDOTHELIN-1 RECEPTOR BLOCKADE IN PATIENTS WITH RESISTANT ARTERIAL HYPERTENSION Phase 2
Withdrawn NCT01939392 - Rapid Renal Sympathetic Denervation for Resistant Hypertension II Phase 2/Phase 3
Recruiting NCT06228677 - Comparison of Catecholamine Concentrations in Venous Blood During Selective Adrenal Artery Embolization
Recruiting NCT04213963 - Prospective Study on Primary Aldosteronism in Resistant Hypertension
Recruiting NCT05563077 - Aerobic Exercise and Resistant Hypertension N/A
Recruiting NCT03758196 - Renal Sympathetic Denervation From the Adventitia on Resistant Hypertension(RSDARH) N/A
Active, not recruiting NCT03179800 - CALM- 2 - Controlling and Lowering Blood Pressure With the MobiusHD™ N/A
Completed NCT04519658 - A Study of CIN-107 in Adults With Treatment-Resistant Hypertension (rHTN) Phase 2
Not yet recruiting NCT05426707 - Remote Ischemic Conditioning for the Treatment of Resistant Hypertension N/A
Not yet recruiting NCT05552300 - Superselective Adrenal Arterial Embolization for Resistant Hypertension N/A
Completed NCT04345198 - Adrenal Artery Ablation for Primary Aldosteronism With Resistant Hypertension N/A
Active, not recruiting NCT05562934 - An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients. Phase 2
Recruiting NCT06034743 - A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension Phase 3
Withdrawn NCT02926495 - Subcutaneous Median Nerve Neuromodulation For Drug-Treatment Resistant Hypertension. N/A
Active, not recruiting NCT02670681 - Effects of Aerobic Exercise on Blood Pressure Levels of Resistant Hypertensive Subjects N/A
Completed NCT02572024 - The Effect of BATon BP and Sympathetic Function in Resistant Hypertension (The Nordic BAT Study) N/A
Terminated NCT02295683 - Renal Sympathetic Denervation by Iberis System in Patients With Uncontrolled Hypertension - Iberis-HTN Registry
Completed NCT02001350 - Carotid Ultrasound Study N/A
Recruiting NCT04331691 - Comparison of Spironolactone and Amiloride on Home Blood Pressure in Resistant Hypertension Phase 4